These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 14634801)

  • 1. Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.
    Potti A; Moazzam N; Langness E; Sholes K; Tendulkar K; Koch M; Kargas S
    J Cancer Res Clin Oncol; 2004 Feb; 130(2):80-6. PubMed ID: 14634801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications.
    Potti A; Hille RC; Koch M
    J Carcinog; 2003 Nov; 2(1):8. PubMed ID: 14617373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas.
    Potti A; Ganti AK; Foster H; Knox S; Hebert BJ; Tendulkar K; Sholes K; Koch M; Kargas S
    Anticancer Res; 2004; 24(1):333-7. PubMed ID: 15015617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma.
    Potti A; Ganti AK; Koch M; Levitt R; Mehdi SA
    Leuk Lymphoma; 2002 Dec; 43(12):2427-30. PubMed ID: 12613538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies.
    Youssef NS; Said AM
    Int J Clin Exp Pathol; 2014; 7(9):5725-37. PubMed ID: 25337214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.
    Potti A; Moazzam N; Tendulkar K; Javed NA; Koch M; Kargas S
    Anticancer Res; 2003; 23(5A):4023-6. PubMed ID: 14666713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi sarcoma.
    Kerr DA; Busarla SVP; Gimbel DC; Sohani AR; Nazarian RM
    Hum Pathol; 2017 Jul; 65():157-165. PubMed ID: 28506734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis.
    Hsieh CY; Chen CA; Chou CH; Lai KP; Jeng YM; Kuo ML; Wei LH
    J Biomed Sci; 2004; 11(2):249-59. PubMed ID: 14966375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma.
    Potti A; Ganti AK; Kargas S; Koch M
    Anticancer Res; 2002; 22(5):2899-901. PubMed ID: 12530014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.
    Konecny GE; Meng YG; Untch M; Wang HJ; Bauerfeind I; Epstein M; Stieber P; Vernes JM; Gutierrez J; Hong K; Beryt M; Hepp H; Slamon DJ; Pegram MD
    Clin Cancer Res; 2004 Mar; 10(5):1706-16. PubMed ID: 15014023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical determination of HER-2/neu in malignant melanoma.
    Potti A; Hille R; Koch M
    Anticancer Res; 2003; 23(5A):4067-9. PubMed ID: 14666720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic value of putative cancer stem cell markers CD117 and CD15 in choroidal and ciliary body melanoma.
    Lukenda A; Dotlic S; Vukojevic N; Saric B; Vranic S; Zarkovic K
    J Clin Pathol; 2016 Mar; 69(3):234-9. PubMed ID: 26290260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma.
    Brunner M; Thurnher D; Pammer J; Geleff S; Heiduschka G; Reinisch CM; Petzelbauer P; Erovic BM
    Mod Pathol; 2008 Jul; 21(7):876-84. PubMed ID: 18408656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of endothelial area with VEGF-A, COX-2, maspin, c-KIT, and DOG-1 immunoreactivity in liposarcomas versus non-lipomatous soft tissue tumors.
    Jung I; Gurzu S; Turdean S; Ciortea D; Sahlean DI; Golea M; Bara T
    Int J Clin Exp Pathol; 2015; 8(2):1776-82. PubMed ID: 25973067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas.
    Li Q; Wang D; Li J; Chen P
    BMC Cancer; 2011 Jun; 11():277. PubMed ID: 21708009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
    Kostopoulos I; Arapantoni-Dadioti P; Gogas H; Papadopoulos S; Malamou-Mitsi V; Scopa CD; Markaki S; Karagianni E; Kyriakou V; Margariti A; Kyrkou E; Pavlakis K; Zaramboukas T; Skordalaki A; Bourli A; Markopoulos C; Pectasides D; Dimopoulos MA; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2006 Apr; 96(3):251-61. PubMed ID: 16538542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
    Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
    Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
    Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
    Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma.
    Potti A; Ganti AK; Tendulkar K; Chitajallu S; Sholes K; Koch M; Kargas S
    Anticancer Res; 2003; 23(3B):2671-4. PubMed ID: 12894556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.